Skip to main content

Prostate Cancer

Comparing the Impact of Abiraterone and Enzalutamide Sequencing on Progression-Free Survival in Veterans with Metastatic Castration-Resistant Prostate Cancer
Nicholas J. Newman, PharmD; Sara E. Gordon, PharmD, BCOP; Charles J. Nock, MD; Christopher J. Burant, PhD; Candice M. Wenzell, PharmD, BCOP
Read More
Meeting Highlights Online Only
Genetic Score Makes PSA Screening More Accurate
Read More
Comparison of Second-Generation Antiandrogens for the Treatment of Prostate Cancer
Seon Jo Park, PharmD, BCOP; Benjamin Yoder, PharmD; Tammy Li, PharmD
Read More
Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer
Read More
Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
Read More
Continuous Treatment with Enzalutamide and Docetaxel Reduces the Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer
Read More
Meeting Highlights
¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Phoebe Starr
Read More
Orgovyx First FDA-Approved Oral Hormone Therapy for Advanced Prostate Cancer
Read More
FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer
Read More
Enzalutamide Administration for a Nonhemodialysis Patient with Stage 4 Chronic Kidney Disease and Nonmetastatic Castration-Resistant Prostate Cancer
So Jung Uhm, PharmD; John Malamakal, PharmD, MS, BCPS, BCOP
Read More
Page 1 of 2
Results 1 - 10 of 13